<DOC>
	<DOC>NCT00919113</DOC>
	<brief_summary>A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.</brief_summary>
	<brief_title>Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome</brief_title>
	<detailed_description>Multi-center, randomized, double-blind, parallel, 8 weekly instillations over a 7-week period with post-treatment follow-up for an additional 19 weeks for a total study length of 26 weeks.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis, Interstitial</mesh_term>
	<criteria>Are a female, 18 years or older Have been diagnosed with IC/PBS Are willing to provide written informed consent and authorization to disclose after being fully informed of the risks of participation Are lactating females Have previously received investigational products or devices within 30 days of screening Have previously received Uracyst Are currently receiving therapy with InterstimÂ® Have any other condition/disease which, in the opinion of the investigator, could compromise subject safety or confound the interpretation of study results Are unable or unwilling to comply with protocol requirements</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Bladder Pain</keyword>
	<keyword>GAG replacement therapy</keyword>
	<keyword>IC/PBS</keyword>
</DOC>